BPC-157 FDA Status in 2026: What Is Approved, Compounded, or Investigational?

BPC-157 is not an FDA-approved drug in 2026. Neither BPC-157 free base nor BPC-157 acetate is a component of an FDA-approved drug, and neither has an applicable United States Pharmacopeia or National Formulary monograph, according to the FDA’s July 2026 compounding review. The FDA’s Pharmacy Compounding Advisory Committee materials also show that the agency proposed against adding either form to the section 503A Bulks List.

The more complicated part is compounding. In October 2026, the Department of Health and Human Services announced a draft, temporary enforcement-discretion policy covering certain peptide bulk substances, including BPC-157. That policy does not turn BPC-157 into an approved drug, establish that it works, or amount to a general authorization for every product sold under its name. It describes limited circumstances in which the government may exercise enforcement discretion while formal rulemaking proceeds.

The 2026 status at a glance

Question Status in 2026 What that means
Is BPC-157 FDA-approved? No FDA has not approved BPC-157 free base or acetate as a drug.
Is it on the final 503A Bulks List? No final inclusion established FDA proposed against listing both forms, while an advisory committee voted in favor. Formal rulemaking remained important to the final outcome.
Can it appear in compounded products? A draft interim policy addresses certain qualifying acetate products Enforcement discretion is conditional, temporary and distinct from approval.
Is BPC-157 investigational? Yes, in the broad evidence sense It has been examined in preclinical and limited human research, but the human evidence does not establish an approved clinical use.
Is it permitted in tested sport? No USADA identifies it as prohibited under the S0 Non-Approved Substances category.

What “not FDA-approved” actually means

FDA approval is tied to a specific drug product, formulation, route, indication and body of evidence. It generally means the agency has reviewed evidence supporting the product’s quality, safety and effectiveness for its labeled use. BPC-157 has not reached that regulatory status.

Calling BPC-157 a peptide, a compounded preparation or an investigational substance does not create an exception to that distinction. A shared molecule name also does not show that products from different sources have equivalent identity, purity, formulation or manufacturing controls.

This is why marketplace availability can be misleading. A product can be advertised or supplied without being an FDA-approved medicine. Likewise, a clinician’s involvement or the word “compounded” does not mean FDA reviewed the finished product for an approved indication.

Where 503A compounding enters the picture

Section 503A describes a federal framework under which state-licensed pharmacies or physicians may compound patient-specific drugs when statutory conditions are met. The label “503A” describes a regulatory category, not a peptide quality grade or an FDA endorsement. Our 503A versus 503B compounding explainer covers the broader distinction.

For a bulk substance to qualify under the relevant 503A condition, it generally must satisfy one of the statutory routes discussed in the federal materials: it can be a component of an FDA-approved drug, have an applicable USP or National Formulary monograph, or appear on a list established through federal rulemaking. FDA’s July 2026 briefing said BPC-157 free base and acetate did not meet the first two routes.

FDA’s Center for Drug Evaluation and Research recommended against placing the two forms on the 503A Bulks List. At the July 23–24 meeting, however, the Pharmacy Compounding Advisory Committee voted in favor of inclusion. The committee’s vote is advisory; it does not itself add a substance to the list or approve a drug.

What changed with the October 2026 enforcement policy

On October 30, 2026, HHS announced a draft interim enforcement-discretion policy for six peptide bulk substances, including BPC-157. The associated Federal Register notice says the draft does not create legal rights and is not binding on HHS or the public.

For BPC-157, the draft describes potential enforcement discretion for qualifying products made with BPC-157 acetate. The conditions address matters such as dosage form, route, patient-specific prescriptions, the ingredient manufacturer, certificates of analysis, reporting and compliance with other applicable laws. It is therefore narrower than a general statement that “compounded BPC-157 is allowed.”

Three distinctions matter:

  • Enforcement discretion concerns whether authorities intend to prioritize enforcement under specified circumstances; it is not FDA approval.
  • The draft policy is temporary while the government completes rulemaking on whether the substances should be included on or excluded from the 503A list.
  • The policy’s discussion of qualifying BPC-157 acetate products should not be automatically extended to every chemical form, route, formulation or seller.

HHS also noted that BPC-157 free base and acetate appeared in FDA’s Category 2 from September 2023 until April 22, 2026. Their removal from that category did not by itself change their legal status under section 503A. Category placement, removal from a category and inclusion on the formal Bulks List are different regulatory events.

Investigational does not mean clinically established

BPC-157 is often described as experimental or investigational because it has been studied without becoming an approved medicine. That description should not be mistaken for proof that it is progressing through a successful clinical-development program or that its proposed benefits have been confirmed in robust human trials.

FDA’s 2026 review identified five human clinical studies in the public literature. The reported exposure was limited and varied widely: the collection included short rectal-enema studies, small knee and bladder injection studies, and a two-person intravenous pilot. These studies did not provide the kind of large, controlled and route-specific evidence normally needed to establish clinical effectiveness and characterize safety.

FDA also identified a registered Phase 1 oral study in Mexico, NCT02637284, but found no posted results or associated published paper. The agency found no human pharmacokinetic data for the nominated oral, subcutaneous, nasal or transdermal routes. Pharmacokinetics describes what happens to a substance in the body, including its absorption, distribution and elimination. Missing route-specific data leaves basic questions about exposure unresolved.

A 2026 sports-medicine review reached a similarly cautious conclusion for musculoskeletal claims. Its authors found only one human musculoskeletal study—a small, retrospective and uncontrolled knee case series—and judged the evidence insufficient to support clinical recommendations for recovery or performance enhancement.

What is known about safety?

The available human reports do not establish that BPC-157 is safe. FDA noted that the human studies it identified did not appear to report serious adverse events, but the studies were small, brief and heterogeneous, with limited or unclear safety monitoring. A study that observes no serious event in a handful of people cannot reliably exclude uncommon, delayed or route-specific harms.

FDA has also raised concerns about possible immune reactions with certain routes, peptide-related impurities and difficulty fully characterizing the active ingredient. The agency said there was insufficient safety information to determine whether BPC-157 could harm people through the proposed routes.

A search of the FDA Adverse Event Reporting System through December 4, 2025 found three reports involving injectable BPC-157 products. Reported events included an injection-site reaction, shortness of breath and pigmentation changes; one product also contained TB-500. FDA emphasized that these reports have substantial limitations. Spontaneous reports can flag questions, but they cannot establish that BPC-157 caused an event or estimate how frequently an event occurs.

The appropriate conclusion is therefore neither “proven dangerous” nor “shown safe.” Human exposure data remain too limited to characterize the risk with confidence. The same evidence principle applies across peptide products: safety depends on the particular molecule, formulation, route, manufacturing quality and strength of the clinical data, as explained in our guide to evaluating whether peptides are safe.

Athletes face a separate anti-doping rule

FDA status and sports eligibility answer different questions. The U.S. Anti-Doping Agency identifies BPC-157 as prohibited under the World Anti-Doping Agency’s S0 Non-Approved Substances category. USADA also reported that BPC-157 would continue to be named under S0 on the 2027 Prohibited List, effective January 1, 2027.

A temporary compounding enforcement policy does not override anti-doping rules. For a tested athlete, the fact that a product came from a healthcare setting or was described as compounded does not make the substance permitted in sport.

The clearest reading of BPC-157’s 2026 status

BPC-157 remained an unapproved peptide in 2026. FDA materials proposed against adding its free-base and acetate forms to the 503A Bulks List, although the advisory committee recommended inclusion. HHS then introduced a draft, conditional enforcement-discretion approach for certain BPC-157 acetate products while formal rulemaking continued. None of those developments amounts to FDA approval.

The clinical evidence is also much weaker than many promotional claims suggest. Human studies are few, small, short and inconsistent in route and design. They cannot establish broad effectiveness for injury recovery, gastrointestinal conditions, performance or other commonly promoted uses, and they leave major safety questions unresolved.

References

  1. July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting
  2. Peptide Enforcement Discretion – Appendix B 10.28.pdf
  3. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee – 07/23/2026 | FDA
  4. exist and the drug substance is not a component of an FDA-approved drug, they appear on a list developed by the Secretary through regulations issued by the Secretary under section 503A(c)(1) (21 U.S.C. § 353a (b)(1)(A)(i)). The Secretary convened and consulted the PCAC as required by statute to issue regulations to implement the 503A bulk peptide list (21 U.S.C. § 353a(c)(1)). FDA must also consul
  5. supplement, concurrent medication use, and a lack of details in the report (i.e. duration of use, temporal relationship to product).
  6. Peptide Supplements and Their Therapeutic Applications in Sports Medicine – Kushagra Tewari, Timothy P. Liu, Christina Im, Christopher Hamad, Frank Petrigliano, Edward C. Cheung, Thomas J. Kremen, 2026
  7. Federal Register Document No. 4164-01-P
  8. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  9. BPC-157: Experimental Peptide Creates Risk for Athletes
  10. www.usada.org

Scroll to Top